- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 215/14 - Radicals substituted by oxygen atoms
Patent holdings for IPC class C07D 215/14
Total number of patents in this class: 468
10-year publication summary
|
28
|
34
|
44
|
37
|
33
|
28
|
24
|
16
|
23
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4742 |
22 |
| Gilead Sciences, Inc. | 2222 |
19 |
| Merck Patent GmbH | 5728 |
8 |
| Neurocrine Biosciences, Inc. | 460 |
7 |
| Merck Sharp & Dohme LLC | 3734 |
7 |
| Novartis AG | 10262 |
6 |
| Agios Pharmaceuticals, Inc | 224 |
6 |
| Santen Pharmaceutical Co., Ltd. | 594 |
6 |
| Janssen Pharmaceutica N.V. | 3168 |
5 |
| Nissan Chemical Industries, Ltd. | 1645 |
5 |
| Taisho Pharmaceutical Co., Ltd. | 852 |
5 |
| University College Dublin, National University of Ireland, Dublin | 357 |
5 |
| Allergan, Inc. | 2167 |
4 |
| Centre National de La Recherche Scientifique | 11023 |
4 |
| Monsanto Technology LLC | 8568 |
4 |
| Alkermes Pharma Ireland Limited | 254 |
4 |
| Ardelyx, Inc. | 119 |
4 |
| Cadila Healthcare Limited | 291 |
4 |
| Imago Biosciences, Inc. | 39 |
4 |
| Toyama Chemical Co., Ltd. | 88 |
4 |
| Other owners | 335 |